Nitric Oxide Generating Gel Dressing in Patients With Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 2 part study to assess the safety and efficacy of a nitric oxide (NOx) generating dressing on chronic diabetic foot ulcers (DFU). Nitric oxide has a range of effects on the body including vasodilation and angiogenesis. It is also a potent antimicrobial. This 140 patient, randomised, controlled clinical study will assess the ability of a simple 2 part, NOx generating dressing to increase blood flow in DFUs and to improve healing in chronic DFUs compared to standard of care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers

NCT04755647

Diabetic Foot Ulcer

COMPLETED PHASE1/PHASE2

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

NCT00613808

Venous Ulcers

TERMINATED PHASE2

Can Topical Oxygen Therapy (Natrox™) Improve Wound Healing in Diabetic Foot Ulcers?

NCT02599805

Diabetic Foot

UNKNOWN PHASE3

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

NCT00764361

Diabetic Foot Ulcer

COMPLETED PHASE2

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

NCT00545298

Venous Ulcers

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a clinical study of a new wound dressing for diabetic foot ulcers (DFU). The dressing consists of 2 stable layers that when placed together release Nitric Oxide. In preclinical studies NOx delivery has caused significant vasodilation, angiogenesis and demonstrated potent anti-microbial activity.

In part 1 of the study, the dressing will be applied to up to 20 DFUs for a set period and the blood flow in and around the wound will be measured before and after application of the dressing. Any adverse events will be recorded.

If an increase in blood flow is seen and the dressing is well tolerated, part 2 will begin, which is a multi-centre, 120 patient, randomised, controlled study. 60 patients with chronic DFUs will be treated with the NOx generating dressing and 60 patients will continue to receive standard of care. The efficacy and the tolerability of the dressing will be measured.

The NOx dressing will be changed at least every 2 days and the standard of care changed as in normal clinical practice.

At weekly clinical visits the diameter, area and volume of the wound will be measured. The infective status of the wound will be assessed and the inflammatory profile of the wound will be measured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.

Group Type EXPERIMENTAL

NOx dressing

Intervention Type DEVICE

The NOx dressing should be changed at least every 2 days.

Control Arm

Standard of Care

Group Type ACTIVE_COMPARATOR

Standard of Care

Intervention Type OTHER

The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NOx dressing

The NOx dressing should be changed at least every 2 days.

Intervention Type DEVICE

Standard of Care

The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients aged over 18 years.
* Diagnosed with type 1 or type 2 diabetes.
* With a chronic (present for at least 6 weeks) full-thickness foot ulcer (on or below the malleoli) not penetrating to tendon, periosteum or bone, and with a cross-sectional area between 25 and 2500 mm2.
* Patients must have pedal blood flow between normal and moderately ischaemic. Measurable as a palpable pedal pulse or in the absence of a palpable pedal pulse they must have a TcPO2 of ≥30mmHg or an ABPI of between 0.5-1.00, or \> 1.2. (An ABPI of \>1.2 is associated with calcification rather than ischaemia. We are including patients with an ABPI \>1.2 because ABPI is measured in large arteries. NOx has the ability to dilate medium to small arterioles which are less likely to be calcified.)
* With some degree of neuropathy (as commonly seen in the Diabetes Foot Clinic).
* Able to read and understand the Volunteer Information Sheet and to provide meaningful written informed consent.
* Able and willing to follow the Protocol requirements.

Exclusion Criteria

* Female patients who are pregnant or breast-feeding
* Any other serious disease likely to compromise the outcome of the trial
* Participation in any clinical study during the eight (8) weeks preceding the dosing period of the study
* Wound area greater than 2500 square mm;
* Patients with severe ischaemia. Measurable as absence of palpable pedal pulse and a TcPO2 of less than 30mmhg, or ABPI \< 0.5 or between 1.0-1.2.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No